Ideaya biosciences announces development candidate nomination of ide892, a potential best-in-class mta-cooperative prmt5 inhibitor

Ide892 is a potent and selective mta-cooperative prmt5 inhibitor with favorable adme properties; demonstrating robust mtap deletion-specific pathway suppression and highly durable antitumor activity in combination with ide397 ind-enabling studies ongoing and targeting ind-filing for ide892 in mid-2025 south san francisco, calif. , dec. 9, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced development candidate nomination of ide892, a potential best-in-class mta-cooperative pmrt5 inhibitor.
MTA Ratings Summary
MTA Quant Ranking